Silicon Valley billionaires are obsessed with 'reprogramming' their bodies for longevity. The first human trial suggests they may be onto something.
The first humans are trying out cellular reprogramming for longevity. It looks like it might be working.
Silicon Valley's elite are investing heavily in the pursuit of longevity by reprogramming their bodies at a cellular level. Tech billionaires Jeff Bezos, Peter Thiel, Yuri Milner, and Sam Altman have all backed startups working on this cutting-edge longevity strategy. The first human trial of cellular reprogramming, conducted at Life Biosciences, shows promising results in rejuvenating glaucoma patients' eyesight.
The experimental therapy involves an eye injection followed by eight weeks of daily antibiotics that activate rejuvenation factors within the patients' cells. So far, there have been no major side effects reported, and two of the three patients have seen significant improvements in their vision. Experts believe the technique has the potential to address a wide range of age-related health issues, from arthritis to Alzheimer's disease.
While the results are preliminary, the positive outcomes have led to a threefold increase in dosage for the next group of participants in the study. Other biotech startups in Silicon Valley are also racing to develop similar therapies for various age-related diseases.
Written by urgent.news from Business Insider's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
